Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial
Royal Marsden NHS Fdn Trust, Dept Med, London, England.;Royal Marsden NHS Fdn Trust, Dept Med, Surrey, England..
Royal Marsden NHS Fdn Trust, Dept Med, London, England.;Royal Marsden NHS Fdn Trust, Dept Med, Surrey, England..
Royal Marsden NHS Fdn Trust, Dept Med, London, England.;Royal Marsden NHS Fdn Trust, Dept Med, Surrey, England..
Royal Marsden NHS Fdn Trust, Dept Med, London, England.;Royal Marsden NHS Fdn Trust, Dept Med, Surrey, England..
Show others and affiliations
2015 (English)In: Annals of Oncology, ISSN 0923-7534, E-ISSN 1569-8041, Vol. 26, no 9, 1936-1941 p.Article in journal (Refereed) Published
Abstract [en]

Lethal-7 (let-7) is a tumour suppressor miRNA which acts by down-regulating several oncogenes including KRAS. A single-nucleotide polymorphism (rs61764370, T > G base substitution) in the let-7 complementary site 6 (LCS-6) of KRAS mRNA has been shown to predict prognosis in early-stage colorectal cancer (CRC) and benefit from anti-epidermal growth factor receptor monoclonal antibodies in metastatic CRC. We analysed rs61764370 in EXPERT-C, a randomised phase II trial of neoadjuvant CAPOX followed by chemoradiotherapy, surgery and adjuvant CAPOX plus or minus cetuximab in locally advanced rectal cancer. DNA was isolated from formalin-fixed paraffin-embedded tumour tissue and genotyped using a PCR-based commercially available assay. Kaplan-Meier method and Cox regression analysis were used to calculate survival estimates and compare treatment arms. A total of 155/164 (94.5%) patients were successfully analysed, of whom 123 (79.4%) and 32 (20.6%) had the LCS-6 TT and LCS-6 TG genotype, respectively. Carriers of the G allele were found to have a statistically significantly higher rate of complete response (CR) after neoadjuvant therapy (28.1% versus 10.6%; P = 0.020) and a trend for better 5-year progression-free survival (PFS) [77.4% versus 64.5%: hazard ratio (HR) 0.56; P = 0.152] and overall survival (OS) rates (80.3% versus 71.9%: HR 0.59; P = 0.234). Both CR and survival outcomes were independent of the use of cetuximab. The negative prognostic effect associated with KRAS mutation appeared to be stronger in patients with the LCS-6 TT genotype (HR PFS 1.70, P = 0.078; HR OS 1.79, P = 0.082) compared with those with the LCS-6 TG genotype (HR PFS 1.33, P = 0.713; HR OS 1.01, P = 0.995). This analysis suggests that rs61764370 may be a biomarker of response to neoadjuvant treatment and an indicator of favourable outcome in locally advanced rectal cancer possibly by mitigating the poor prognosis of KRAS mutation. In this setting, however, this polymorphism does not appear to predict cetuximab benefit.

Place, publisher, year, edition, pages
2015. Vol. 26, no 9, 1936-1941 p.
Keyword [en]
LCS-6 KRAS variant, single-nucleotide polymorphism, let-7, KRAS, cetuximab, rectal cancer
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:uu:diva-264637DOI: 10.1093/annonc/mdv285ISI: 000361392700020PubMedID: 26162609OAI: oai:DiVA.org:uu-264637DiVA: diva2:862131
Funder
EU, FP7, Seventh Framework Programme, CIG 334261
Available from: 2015-10-20 Created: 2015-10-15 Last updated: 2017-12-01Bibliographically approved

Open Access in DiVA

fulltext(228 kB)46 downloads
File information
File name FULLTEXT01.pdfFile size 228 kBChecksum SHA-512
36812afc769c5734487e75bf626f3854ac5f6e962fc1a16deb7440a04264c16f7fd9b1b5edea7496b32482f6039833050b1b676d0459f90de8a25dc76b41e133
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Glimelius, Bengt
By organisation
Experimental and Clinical Oncology
In the same journal
Annals of Oncology
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
Total: 46 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 375 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf